Johnson & Johnson (JNJ) Releases Quarterly Earnings, Beats Expectations By $0.04 EPS
Johnson & Johnson (NYSE:JNJ) announced its earnings results on Tuesday. The company reported $1.36 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.32 by $0.04, AnalystRatingsNetwork.com reports. The company had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $17.46 billion.
JNJ has been the subject of a number of recent research reports. Analysts at Thomson Reuters/Verus downgraded shares of Johnson & Johnson from a “hold” rating to a “sell” rating in a research note to investors on Monday. On the ratings front, analysts at Goldman Sachs Group Inc. upgraded shares of Johnson & Johnson from a “sell” rating to a “neutral” rating in a research note to investors on Friday. They now have a $95.00 price target on the stock, up previously from $87.00. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Johnson & Johnson in a research note to investors on Friday, August 30th. They now have a $91.00 price target on the stock. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and seven have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $88.29.
Johnson & Johnson (NYSE:JNJ) opened at 89.80 on Tuesday. Johnson & Johnson has a 52-week low of $68.51 and a 52-week high of $94.42. The stock’s 50-day moving average is $87.71 and its 200-day moving average is $87.29. The company has a market cap of $253.1 billion and a price-to-earnings ratio of 19.93.
Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a broad range of products in the health care field.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.